New blood-thinner study for heart disease patients in China
Part of Heart & circulation clinical trials.
This study tests a new medication called selatogrel in people with chronic coronary syndrome (long-term heart disease caused by narrowed heart arteries). Researchers want to see how the body processes this drug and whether it helps prevent future heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic coronary syndrome (narrowed heart arteries confirmed by heart catheterization or CT scan, or a previous heart attack more than 3 months ago)
- You are currently taking aspirin as your only blood-thinner medication, and have been taking it steadily for at least 1 month
- You weigh at least 110 pounds (50 kg)
- You have not had a heart attack, stent, bypass surgery, or stroke within the past 3 months
- You do not have serious liver or kidney disease, recent bleeding problems, or a hemoglobin level below 10 g/dL
- You have not taken another experimental drug in the past 3–6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of dual antiplatelet therapy (aspirin plus ticagrelor) after stent placement, switching early to just ticagrelor alone. It aims to see if this approach can safely reduce bleeding risks while still protecting against heart problems in people with stable coronary artery disease.
This study tests whether a new drug called HRS9531 can help people with atherosclerotic cardiovascular disease (hardened arteries affecting the heart and blood vessels). The trial will check if it's safe and effective for managing this condition.
This trial tests selatogrel to see if it can better prevent harmful heart and blood-clot outcomes after a recent heart attack. You may be considered if you had a heart attack in the past 4 weeks and have higher-risk heart artery disease.
This study tests how a new blood-thinning medication (CG-0255) works in the body and compares it with Plavix, a common blood thinner. Researchers will measure how much of the drug enters your bloodstream and what effects it has on your blood clotting ability.
This trial studies a drug-coated balloon (plus standard heart medicines) to treat a specific type of blockage in the heart arteries in people who need an intervention. It may help keep the artery open and prevent the narrowing from coming back, depending on how well you match the detailed heart and medication requirements.
This trial tests whether tailoring anti-platelet (blood clot prevention) treatment can better protect people at higher risk of heart or blood-vessel problems after a drug-eluting stent. It may help prevent future clots and complications, especially in patients with certain high-risk health conditions or complex stent/scar tissue features.
Hear when a new Chronic Coronary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.